Raiffeisen Bank International AG Takes Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Raiffeisen Bank International AG bought a new position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 430,000 shares of the company's stock, valued at approximately $903,000. Raiffeisen Bank International AG owned 0.21% of Allogene Therapeutics as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Lynx1 Capital Management LP boosted its holdings in shares of Allogene Therapeutics by 75.3% during the fourth quarter. Lynx1 Capital Management LP now owns 10,874,723 shares of the company's stock worth $23,163,000 after acquiring an additional 4,672,349 shares during the period. Dimensional Fund Advisors LP boosted its stake in Allogene Therapeutics by 30.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,561,626 shares of the company's stock valued at $7,586,000 after purchasing an additional 831,146 shares during the period. Foresite Capital Management VI LLC bought a new position in Allogene Therapeutics during the 4th quarter worth $7,345,000. Patient Square Capital LP acquired a new stake in shares of Allogene Therapeutics during the fourth quarter worth $3,174,000. Finally, Northern Trust Corp boosted its position in shares of Allogene Therapeutics by 4.5% in the fourth quarter. Northern Trust Corp now owns 1,305,232 shares of the company's stock valued at $2,780,000 after acquiring an additional 56,693 shares during the period. Institutional investors and hedge funds own 83.63% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Piper Sandler lowered their price target on shares of Allogene Therapeutics from $9.00 to $7.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 14th. Canaccord Genuity Group restated a "buy" rating and set a $14.00 target price on shares of Allogene Therapeutics in a research report on Friday, March 14th. Oppenheimer dropped their price target on shares of Allogene Therapeutics from $10.00 to $9.00 and set an "outperform" rating for the company in a research report on Wednesday, May 14th. HC Wainwright cut their price target on Allogene Therapeutics from $9.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday, March 19th. Finally, Truist Financial reduced their price target on Allogene Therapeutics from $14.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $8.44.

Allogene Therapeutics Stock Performance

Shares of NASDAQ ALLO traded down $0.02 during trading hours on Thursday, hitting $1.10. 387,394 shares of the stock were exchanged, compared to its average volume of 3,330,398. The company's fifty day simple moving average is $1.43 and its two-hundred day simple moving average is $1.89. The company has a market cap of $239.51 million, a PE ratio of -0.70 and a beta of 0.60. Allogene Therapeutics, Inc. has a 1-year low of $0.86 and a 1-year high of $3.78.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.28) earnings per share for the quarter, hitting the consensus estimate of ($0.28). As a group, sell-side analysts expect that Allogene Therapeutics, Inc. will post -1.28 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO David D. Chang sold 46,668 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $1.96, for a total value of $91,469.28. Following the sale, the chief executive officer now directly owns 5,276,569 shares in the company, valued at approximately $10,342,075.24. This trade represents a 0.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 61,757 shares of company stock worth $115,873 in the last ninety days. 13.20% of the stock is owned by insiders.

Allogene Therapeutics Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).